. There were 63,162 adult patients receiving renal replacement therapy (RRT) in the UK on 31 December 2016, an absolute increase of 3.1% from 2015. . The actual number of patients increased by 0.9% for haemodialysis (HD), 5.1% for those with a functioning transplant and less than 0.1% for peritoneal dialysis (PD). . The UK adult prevalence of RRT was 962 per million population (pmp). The reported prevalence in 2000 was 523 pmp.
. The number of patients receiving home HD increased slightly from 1,175 patients in 2015 to 1,256 patients in 2016. . In 2016 the median age of prevalent patients was 59 years (HD 67 years, PD 64 years, transplant 54 years). In 2000 the median age was 55 years (HD 63 years, PD 58 years, transplant 48 years). The percentage of RRT patients aged greater than 75 years in 2016 was 16.0%. . For all ages, RRT prevalence in men exceeded that in women, peaking in age group 80-84 years at 3,072 pmp in men and in the 70-74 years age group at 1,657 pmp in women. . The most common identifiable renal diagnosis was glomerulonephritis (19%), followed by diabetes (17%), other (17%) and aetiology uncertain (15%). . Transplantation continued as the most common treatment modality (54%), HD was used in 40% and PD in 6% of RRT patients.
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Introduction
This chapter presents data on all adult patients on RRT in the UK at the end of 2016. The UK Renal Registry (UKRR) received data returns for 2016 from all five renal centres in Wales, all five in Northern Ireland and 51 in England. Cambridge renal centre (Addenbrooke's) was unable to submit 2015 or 2016 data at patient level prior to the UKRR closing the database and only provided summary numbers of patients starting RRT by treatment modality. This centre is therefore excluded from most analyses in this chapter. Data from all nine centres in Scotland were obtained from the Scottish Renal Registry. Demographic data on children and young adults can be found in chapter 4.
These analyses of prevalent RRT patients are performed annually to aid clinicians and policy makers in planning future RRT requirements in the UK. It is important to understand national, regional and centre level variation in numbers of prevalent patients as part of the capacity planning process. In addition, knowledge about variation in case mix is also reported to improve understanding of where resources should be focussed to improve equity of provision of RRT in the UK.
The term established renal failure (ERF) used within this chapter is synonymous with the terms end stage renal failure and end stage renal disease, which are in more widespread international usage. Patients have disliked the term 'end stage' which reflects the inevitable outcome of this disease.
Methods
Crude prevalence ratios were calculated pmp and age/sex standardised prevalence ratios were calculated as detailed in appendix D: Methodology used for Analyses of Clinical Commissioning Group (CCG)/Health Board (HB) Incidence and Prevalence Rates and of Standardised Ratios (www.renalreg.org).
Throughout this chapter, HD refers to all modes of HD treatment, including haemodiafiltration (HDF). Several centres reported significant numbers of patients on HDF, but other centres did not differentiate this treatment type in their UKRR returns. Where joint care of renal transplant recipients between the referring centre and the transplant centre occurred, the patient was usually allocated to the referring centre (see appendix B2 for the allocation procedure). Thus the number of patients allocated to a transplant centre is often lower than that recorded by the centre itself and conversely, pre-emptively transplanted patients were sometimes allocated to the transplanting centre rather than the referring centre if no transfer out code had been sent through. Queries and updated information are welcomed by the UKRR at any point during the year if this has occurred.
Prevalent patients on RRT in 2016 were examined by time on RRT, age group, sex, ethnic origin, primary renal disease, presence of diabetes and treatment modality (see appendix H: Coding, www.renalreg.org). In the analysis of prevalence, only adult patients on RRT contributed to the numerator and denominator.
Time on RRT was defined as median time on treatment and was calculated from the most recent start date. Patients without an accurate start date were excluded from this calculation.
Analyses were done for the UK as a whole, by UK country, at centre level and split by treatment modality when appropriate.
Chi-squared test, Fisher's exact test, linear regression and Kruskal Wallis tests were used as appropriate to test for significant differences between groups. The data were analysed using SAS 9.3.
Results

Prevalent patient numbers and changes in prevalence
The number of patients for each country (table 2.1) was calculated by totalling the number of patients in each renal centre located in the country. These numbers differ marginally from those quoted elsewhere in this report when patients are allocated to geographical areas by their individual post codes, because some centres treat patients from across national boundaries. There were 63,162 adult patients receiving RRT in the UK at the end of 2016, giving an adult UK population prevalence of 962 pmp (table 2.1) compared with 941 pmp in 2015. RRT prevalence increased in all UK countries in 2016. Since 2015 the prevalence of dialysis in the UK remained steady at 440 pmp and there were increases in the prevalence of transplant from 501 pmp in 2015 to 522 in 2016. There had been a slow decline in PD prevalence in previous years, but prevalence in 2016 remained at the same level as in 2015. As observed in the previous year, Northern Ireland exhibited a higher RRT prevalence for patients aged 75 years and older compared with the other UK countries (figure 2.1). In the UK, RRT prevalence in patients aged 80-84 continued to rise from 2,044 per million age related population (pmarp) in 2015 to 2,098 pmarp in 2016 and in patients aged 585 years from 1,084 pmarp in 2015 to 1,129 pmarp in 2016. This trend has been remarked upon over a number of years and the observed aging of the prevalent population is likely due in part to improving patient survival.
Prevalent patients by RRT modality and centre
There was a marked variation in the number of prevalent patients across renal centres and the distribution of their treatment modalities also varied widely (table 2. 2).
Changes in prevalence
The prevalent UK RRT population grew by 3.2% between 2015 and 2016 (table 2. 3), an annual growth rate which has been fairly consistent over the last 10-15 years (figure 2.2).
The increase in prevalence was greatest in Northern Ireland (4.6%) and most modest in Wales (0.9%).
The number of prevalent HD patients increased by 0.1% in 2016 compared with 2015, which was a much smaller increase than that seen between 2014 and 2015 (2.7% growth in prevalence pmp). There continued to be an increase in prevalent transplant patients (4.2% pmp) and very little change in prevalent PD patients (0.6% pmp decrease).
The average annual change in prevalent patients between 2012 and 2016 was a 1.0% pmp increase in HD, 2.1% pmp fall in PD and 4.6% pmp growth in prevalent transplant patients (table 2.4). In the same period there was an average annual 15.5% pmp growth (an absolute increase of 451 from 737 to 1,188) in the use of home haemodialysis (data not shown).
The long-term (1997-2016) UK prevalence pattern by treatment modality is shown in figure 2.2. The steady growth in transplant numbers was maintained in 2016.
The increase in home haemodialysis patient numbers over this period has been associated with more than a doubling in prevalence, from 1. The need for RRT depends upon many factors such as primary renal diagnosis, but also on social and demographic factors such as age, sex, social deprivation and ethnicity. Hence, comparison of crude prevalence ratios by geographical area can be misleading. This section, as in previous reports, uses age and sex standardisation to compare RRT prevalence. The ethnic minority profile is also provided to help understand the differences in standardised prevalence ratios (SPRs).
There were substantial variations in the crude CCG/ HB prevalence ratios pmp (table 2.5), from 639 pmp in Lincolnshire (NHS South West Lincolnshire, population 125,200) and 641 pmp in Orkney (Orkney, population 21,900) to 1,773 pmp in Brent (NHS Brent, population 328,300). However, as described in table 2.5, estimates for some CCGs (denoted with an a,b in table 2.5, including NHS South West Lincolnshire) may be underestimated given that 5-15% of patients from these CCGs were estimated to be treated at the Cambridge renal centre, which was unable to provide patient-level data in 2015 or 2016.
There were similar variations in the SPRs (ratio of observed: expected prevalence given the age/sex breakdown of the CCG/HB) from 0.57 (Orkney) to 2.37 (NHS Bradford City) ( In 2016, there were 77 CCGs/HBs with a significantly low SPR, 103 with a 'normal' SPR and 45 with a significantly high SPR (table 2.5). Prevalence ratios were not estimated for eight CCGs where more than 15% of patients were estimated to be treated at the Cambridge renal centre which was unable to provide patient-level data.
As seen in previous years, SPRs tended to reflect the demographics of the regions in question such that urban, ethnically diverse populations in areas of high social deprivation had the highest prevalence of RRT. For example, the association with the level of ethnic diversity is illustrated by the fact that mean SPRs were significantly higher in the 84 CCGs/HBs with an ethnic minority population greater than 10% than in those with lower ethnic minority populations (p , 0.001). There was a strong, positive correlation between the are clearly important in explaining differences in SPR they are not the only explanation. The age and sex SPRs (which do not take into account variation in ethnicity) in each region of England and in Wales, Northern Ireland and Scotland are presented in table 2.6. Wales and Northern Ireland previously had higher than expected RRT prevalence but in more recent years were similar to expected. Scotland had lower than expected RRT prevalence as did the North and South of England. RRT prevalence in London remained higher than expected.
Case mix in prevalent RRT patients
Time on RRT (vintage) Table 2 .7 shows the median time, in years, since starting RRT of prevalent RRT patients on 31 December 2016. Median time on RRT for all prevalent patients has remained fairly static at 6.2 years (6.2 years in 2015, 6.1 years in 2014). Patients with functioning transplants had survived a median of 10.3 years on RRT whilst the median time on RRT of HD and PD patients was significantly less (3.2 and 1.5 years respectively). The median time on HD was more than double that on PD and this could reflect early transplantation in the latter as well as higher technique failure rates for PD.
Age
The median age of prevalent UK patients on RRT at 31 December 2016 (59.1 years, table 2.8) has remained stable over recent years although it is significantly higher than in 2005 when it was 55.0 years. As observed previously, there were marked differences between modalities; the median age of HD patients (67.2 years) was greater than that of those on PD (63.7 years) and substantially higher than that of transplanted patients (54.3 years). Of the UK prevalent RRT population, 49.9% were in the 40-64 years age group (table 2.9). The proportion of patients aged 75 years and older varied greatly between countries and was highest in Wales (17.8%) and Northern Ireland (18.4%) and lowest in Scotland (12.5%) (table 2.9). Within countries there were large differences in the proportion of patients aged over 75 (within England these ranged between 8.8% in Liverpool Royal Infirmary and 41.4% in Colchester). In most centres the prevalent PD population was younger than the HD population (table 2.8).
Inter-centre differences in the median age of prevalent patients by treatment modality can reflect differing demographics of the catchment populations as well as differing approaches to treatment modalities. For example, Colchester had the highest median age (72.0 years), whilst London Guy's the lowest (55.3 years) (table 2.8). This could reflect either variation in the catchment populations or follow-up of younger transplant patients (Colchester had no transplant patients whereas 65% of prevalent patients at London Guy's were transplant patients). The median age of the non-White dialysis population was lower than the overall dialysis population (62.0 vs 66.8 years, data not shown). The differing age distributions of the transplant and dialysis populations are illustrated in figure 2.4, demonstrating that the age peak for prevalent dialysis patients was 24 years later than for prevalent transplant patients.
In the UK on 31 December 2016, 66.3% of patients on RRT aged less than 65 years had a functioning transplant (table 2.15), compared with only 32.6% of those aged 65 years and over. There was a similar pattern in all four UK countries, although the proportion of patients aged less than 65 years with a functioning transplant in Northern Ireland (77.4%) was much higher than elsewhere.
Sex
The age distributions of males and females were very similar (data not shown). Standardising the age of the MacNeill/Ford/Evans/Medcalf MacNeill/Ford/Evans/Medcalf UK RRT prevalent patients by using the age and sex distribution of the UK population by CCG/HB (from mid-2016 population estimates), allowed estimation of crude prevalence by age and sex (figure 2.5). This shows a progressive increase in prevalence with age, peaking at 2,276 pmp (similar to the 2,270 pmp estimate in 2015) in the age group 75-79 years then a rapid decline thereafter. Crude RRT prevalence in males exceeded that of females for all age groups. The difference was smallest in younger patients and was greatest from the age of 70 years onwards. RRT prevalence in males was highest in the 80-84 years group (3,072 pmp) and for females it was in the 70-74 years group (1,657 pmp). Survival on RRT by sex is described in chapter 5.
Ethnicity
Key to understanding differences in RRT prevalence between regions is understanding the ethnic diversity of improving however and only three years ago was 23%. In 2016, completeness of ethnicity data was highest in prevalent transplant patients (42.6%) which likely reflects improved data recording during the intensive work-up for transplantation. In 2016, 23.6% of the prevalent UK RRT population (with ethnicity assigned) were from ethnic minorities (25.6% in England). The proportion of the prevalent UK RRT population (with ethnicity assigned) from ethnic minorities in Wales, Scotland and Northern Ireland was very small, although it should be noted that there was a high level of missing ethnicity data in Scotland as described above. The Office of National Statistics estimates that approximately 13% of the UK general population is designated as belonging to an ethnic minority [1] . The relative proportion of patients reported to the UKRR as receiving RRT and belonging to an ethnic minority has increased from 14.9% in 2007 to 23.6% in 2016, which may reflect improvements in coding and reporting of ethnicity data as well as an increasing incidence of ERF and increased referral rates in these populations.
Amongst the centres with more than 50% returns there was wide variation in the proportion of patients from ethnic minorities, ranging from 0.4% in Antrim to 64.7% in London St Bartholomew's.
Primary renal diagnosis
Primary renal diagnosis (PRD) is associated with patient outcomes and as it could be used for case-mix adjustment, high levels of data completeness are important. Data for PRD were not complete for 3.2% of patients (table 2.11), but there existed a marked inter-centre difference in completeness of data returns. One centre had 540% PRD data coded as uncertain and has been excluded from the inter-centre analysis and other analyses where PRD is included in the case-mix adjustment (Colchester, 46% uncertain PRD); the UK and national totals have been appropriately adjusted. The percentage of patients with uncertain aetiology for the remaining 69 centres providing individual-level data ranged between 4.3% and 32.9%, which is comparable to recent years. No centre had .30% missing data in 2016.
As observed in previous years, glomerulonephritis (GN) is the most common PRD in the 2016 prevalent cohort at 19.1% (table 2.11). Diabetic nephropathy is the next most common PRD and accounted for 16.9% of renal disease in prevalent patients on RRT, although it was more common in the 565 year age group compared to the younger group (18.9% vs 15.7%). The distribution of individual PRDs varied with age; patients aged 65 years and younger were more likely to have GN (21.5%) or diabetes (15.7%) and less likely to have renal vascular disease (1.0%) as the cause of their renal failure. This contrasts with older patients (565 years) among whom 6.3% had renal vascular disease as the cause of their renal failure. Uncertain aetiology was a more common cause in this age group than amongst younger patients (18.1% compared with 13.6% amongst patients ,65 years).
As described in previous years, the male : female ratio was greater than 1 : 1 for all PRDs (table 2.11). The biggest differences between males and females were for GN (male : female ratio of 2.1), hypertension (2.5) and renal vascular disease (2.0).
Older and younger patients had markedly different trends in the transplant : dialysis ratio by PRD. In individuals aged less than 65 years, the renal transplantation to dialysis ratio was greater than 1 in all PRD groups except diabetic nephropathy and renal vascular disease. In those aged 565 years, dialysis was more prevalent than renal transplantation in all PRD groups except GN and polycystic kidney disease (PKD) (table 2.12).
Diabetes
Throughout this section the term 'diabetic nephropathy' is used to denote patients in whom diabetes mellitus is considered to be the primary cause of the kidney disease rather than merely an associated comorbidity. It includes all prevalent patients with type 1 or type 2 diabetes as the PRD (ERA-EDTA coding). This analysis did not differentiate between type 1 and type 2 diabetes The number of prevalent patients with diabetic nephropathy has increased steadily over the last number of years and grew by 4.7% to 10,375 in 2016, from 9,913 in 2015, representing 17.4% of all prevalent patients (compared with 13.5% in 2006) (table 2.13). Men were 1.66 times more likely to have diabetic nephropathy than women. The median age at start of RRT for patients with diabetic nephropathy (56 years) was nine years higher than those with other PRDs (47 years), although the median age at the end of 2016 for prevalent patients with diabetic nephropathy was only four years higher than for individuals without diabetic nephropathy. This reflects reduced survival for patients with diabetes compared with patients without diabetes on RRT. This is also supported by the lower median time on RRT for patients with diabetic nephropathy (3.6 years vs 7.5 years for those without diabetic nephropathy) and this difference in survival has not changed over the last five years (3.4 years in 2016 vs 6.5 years in 2011). The age at starting RRT in those with diabetic nephropathy was four years younger in Scotland compared with the UK average (data not shown).
Patients with diabetic nephropathy had a different distribution of RRT modalities than those without diabetes. Fifty eight percent of patients with diabetic nephropathy were undergoing HD compared with just 36% of patients with any other PRD (table 2.13). The percentage of patients with a functioning transplant was much lower in prevalent patients with diabetic nephropathy than in prevalent patients without (34% vs 59%). The proportion of patients with diabetic nephropathy with a functioning transplant has increased however since 2006 when only 27% of patients with diabetic nephropathy had a functioning transplant. For older patients with diabetic nephropathy (age 565 years), only 15.1% had a functioning transplant compared with 47.8% of their peers with a transplant aged under 65 years (table 2.14). Amongst those patients receiving dialysis, a higher proportion of prevalent patients without diabetic nephropathy (18.1%) were on home dialysis therapies (home HD and PD) compared with prevalent patients with diabetic nephropathy (14.1%). Both of these trends (those with diabetic nephropathy being more likely to be doing home dialysis than those with other PRDs and less likely to be transplanted) were consistent across all age groups (18-39 years, 40-64 years, 65-74 years, 75 + years), although as expected the greatest proportion transplanted in both groups are those aged 18-39 years (data not shown).
Modalities of treatment
Transplantation was the most common treatment modality (53.9%) for prevalent RRT patients in 2016, followed by centre-based HD (38.3%) in either hospital centre (17.5%) or satellite unit (20.8%) (figure 2.6). Satellite HD was again more prevalent than in-centre HD, a trend first noted in 2012. Home therapies made up the remaining 7.9% of treatment therapies, largely PD in its different formats (5.9%) which has followed a similar pattern since 2012. The proportion on continuous ambulatory PD (CAPD) and automated PD (APD) was 2.4% and 3.5% respectively, although the proportion on APD Of the dialysis population, 45.1% received their treatment at a satellite HD unit in 2016. This figure remained comparable to recent years, but represented an increase from 39.9% in 2010. In 2016, the number of centres that had more than 50% of their HD activity taking place in satellite units was 27 (figure 2.8). Although there were satellite units in Scotland, the data provided for 2016 did not distinguish between main centre and satellite unit HD. As such, it is difficult to accurately assess access to satellite HD across the UK as a whole so statistics pool only England, Wales and Northern Ireland. There was also wide variation between centres in the proportion of dialysis patients being managed with APD, ranging from 0.0% to 24.0% (table 2.16). While in Northern Ireland nearly all PD patients were on APD, across the UK six of the 69 centres with a PD programme did not report having any patients on APD.
Home haemodialysis
In 2016, the percentage of dialysis patients receiving home HD varied from 0% in five centres, to 5% or greater in 24 centres (table 2.16). In the UK, the overall percentage of dialysis patients receiving home HD has increased from 3.4% in 2011 to 4.4% in 2016.
The proportion of dialysis patients receiving home HD was greatest in Wales at 6.8%, compared with 2.4% in Northern Ireland, 4.5% in England and 2.5% in Scotland (figure 2.8, table 2.16). By comparison, in 2007, the proportion of patients receiving home HD was 2% in each of the four UK countries. More recently, 30 renal centres across the UK had an increase in the proportion of individuals on home HD compared with 2015.
Change in modality
The relative proportion of RRT modalities in prevalent patients has changed dramatically over the past 16 years. Figure 2 .10 depicts in more detail the modality changes in the prevalent dialysis population during this time. The data show a clear reduction in patients treated by CAPD over time and an increase in satellite HD coupled with a reduction in hospital HD.
International comparisons
There were marked differences in RRT prevalence between countries (figure 2.11). RRT prevalence in Northern European countries (including the UK), Australia and New Zealand was lower than in Southern Europe which was lower than the USA, Canada and Japan. Identifying the source of these differences is complicated by differences in healthcare systems, patient registry coverage, approaches to conservative care and incidence rates in these countries. 
Discussion
Prevalence of RRT continued to increase in the UK, with an absolute increase in the number of adults receiving RRT of 3% between 2015 and 2016. The majority of this increase was in people with a functioning renal transplant (5% increase); with a 1% increase in the number of people receiving HD. There was significant variation between centres in the change in the number of prevalent RRT patients between 2015 and 2016; one centre experienced a 4% fall whereas another had a 20% increase. Whether this variation reflects local differences or recent changes in RRT choices, a one-off movement of patients, historical differences in dialysis planning, or differences in genuine need for RRT would require local interpretation.
The change in prevalence of RRT represents a balance between new patients to RRT (discussed in chapter 1 on incidence), movements between treatment types (discussed particularly in chapter 9 on access to transplantation) and mortality (discussed in chapter 5 on survival). Occasionally it can be artefactual due to a change in reporting practice by centres. The growth in the prevalence of adults with a functioning transplant for example, in part represents the success of recent increases in transplant numbers and a lower mortality rate (compared with those receiving dialysis).
There have been constraints such as historic in-centre HD capacity because of high capital costs, people requiring a renal transplant being limited by the availability of donor organs and people preferring home therapies being limited by access to equipment or training resources. Therefore, it is not possible to conclude from this report whether the prevalence of RRT (in its entirety or by modality) reflects the genuine need for RRT in a particular locality or whether there was (currently unmeasured) unmet need. The UKRR has started collecting information about patients with CKD stage 4 and 5 from renal centres which it is hoped will enable a better description of the prevalence of people with CKD5 not on dialysis. This will include those having dialysis preparation, those waiting to start RRT and those having conservative kidney care which will help assess this further in future years. PD as a treatment type continued to grow very slowly in absolute numbers and has decreased as a proportion of all those on RRT. The numbers of people treated by home HD continued to increase (an average annual increase of 15% pmp since 2012) but this was from a low base so represents an increase from 737 patients in 2012 to 1,188 in 2016. Increasing the number of people able to dialyse at home is one of the three priorities identified by the Kidney Quality Improvement Partnership (KQuIP) along with vascular access and transplant first. At regional KQuIP meetings, several local renal teams have identified access to home therapies and renal transplantation as topics that they will work to improve in the coming year. Evaluation of their efforts on these priorities will be collected and published through the UKRR annual report, allowing teams to focus their efforts on the improvement programmes themselves and is a good example of how a national registry can help facilitate local improvement.
The population of the UK continues to age which was also reflected in the population receiving RRT with a median age of 59 years compared with 55 years in the year 2005. Age appears to be one of a group of factors (including diabetes as PRD) which influences the proportions on each RRT modality. Patients with a functioning renal transplant are younger on average (54 years) than those on PD (64 years) and (predominantly incentre) HD (67 years). Whilst age confounds the treatment modality for those with diabetes as the cause of their ERF, at any age the proportion of those with diabetes who have a functioning renal transplant was lower than those who had an alternate cause of ERF.
Chronic kidney disease (CKD) is associated with several conditions which increase in prevalence with age (diabetes, hypertension and cardiovascular disease for example). It is unsuprising therefore that the peak prevalence of RRT pmp was in the 80-84 age group for men and the 70-74 age group for women. The prevalence of CKD stages 3-5 was higher amongst women in the UK either in GP practice populations [3] , or health surveys [4] and women in the UK general population have a longer life expectancy than men [5] . Whilst it is thought that women progress to ERF more slowly [6] and once on dialysis lose their general population survival advantage over men [7] , the full explanation for why in contrast a greater proportion of people receiving RRT were men is not known. Information obtained from patients in renal centres with CKD 4-5 may help unravel this paradox better in the future.
